固定科研人员/Faculty

赵西林/Xilin Zhao

发布时间:2015/7/22 浏览量:1422

赵西林(Xilin Zhao)教授

1984–1990:天津南开大学生物系/分子生物学研究所, 生物化学学士/分子生物学硕士

2002–2003:英国John Innes Centre/BBSRC-Univ. East Anglia,微生物与分子生物学博士

1991–1993:南开大学分子生物学研究所研究实习员、助理研究员

1994–2001:美国纽约公共健康研究所(PHRI)研究科学家(Research Scientist)

2003–现在: 美国新泽西公共健康研究所(PHRI)副研究员(Research Associate Member), 首席研究员(Principal Investigator)

2006–2013.6:美国新泽西医科与牙医大学(UMDNJ)新泽西医学院(NJMS)微生物与分子遗传学系 兼职助理教授、副教授

2013.7– 现在:美国新泽州立罗格斯(Rutgers)大学、新泽西医学院(NJMS)、微生物与分子遗传学系 兼职副教授

2012–现在:厦门大学公共卫生学院教授。

研究成果与研究领域:长期从事抗生素作用机制与耐药、结核病新疗法、细菌应急应答等方向研究,已在Cell Reports、PNAS、NJEM、CID、JID、Lancet ID、Mol Microbiol等国际知名刊物发表论文77篇,SCI总引用次数超过3000次,单篇SCI最高引用次数657次。与国际著名拓扑异构酶和喹诺酮领域专家Karl Drlica教授共同创立了抗生素耐药的耐药突变体选择窗(Mutant Selection Window (MSW))理论,该理论及其重要参数(耐药突变体预防浓度Mutant Prevention Concentration (MPC))已被广泛认可,其中与MPC、MSW有关的论文报道已有350余篇,且MPC和MSW均已被JAC、AAC等国际刊物列为自动选项关键词。纠正了喹诺酮杀菌必须依赖DNA复制这一误导该领域研究多年的谬误,发现了喹诺酮母核8位 甲氧基化及卤化与增强杀菌活性和减少耐药的构效关系。最近阐明了细菌致死性应激应答反应与抗生素杀菌、耐药的关系,已获得两个全新抗生素增效剂靶蛋白。独 辟蹊径地发现并建立了一种全新的结核病气体疗法。一旦获得临床验证,该方法有望在几天甚至几小时内治愈肺结核。因其独创性及巨大潜在社会、经济价值,该项 目研究分别获得NIH院长新发明人创新奖(NIH Director’s New Innovator Award)及比尔盖茨基金会GCE两次资助。

近期主要论著(*通讯作者)

[1] Dorsey-Oresto A, Lu T, Mosel M, Wang X, Salz T, Drlica K, Zhao X* (2013) YihE kinase is a central regulator of programmed cell death in bacteria. Cell Reports 3 (2): 528-537.

[2] Yuan X, Liu Y, Bai C, Luo Y, Wang R, Wang R, Cai Y, Zhao X* (2013) Mycoplasma pneumoniae infection is associated with subacute cough. Eur Respir J. [Epub ahead of print]

[3] Mosel M, Li L, Drlica K, Zhao X* (2013) Superoxide-mediated protection of Escherichia coli from antimicrobials. Antimicrob Agents Chemother. 57: 5755-9.

[4] Liu Y, Liu X, Qu Y, Wang X, Li L, Zhao X* (2012) Inhibitors of reactive oxygen species accumulation delay and/or reduce the lethality of several antistaphylococcal agents. Antimicrob Agents Chemother 56: 6048-50.

[5] Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X* (2011) Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 55: 2409-12.

[6] Wu X, Wang X, Drlica K, Zhao X* (2011) A toxin-antitoxin module in Bacillus subtilis can both mitigate and amplify effects of lethal stress. PLoS ONE 6 (8): e23909.

[7] Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 65: 520-524.

[8] Wang X, Zhao X* (2009) Contribution of oxidative damage to antimicrobial lethality. Antimicrob Agents Chemother 53:1395-402.

[9] Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52: 385-92.

[10] Cui, J., Liu, Y., Wang, R., Tong, W., Drlica, K., and Zhao, X*. (2006). The mutant selection window in rabbits infected with Staphylococcus aureus.J. Infect. Dis. 194: 1601-8.

[11] Malik M, Zhao X, Drlica K (2006) Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol 61: 810-25.

[12] Zhao X, Malik M, Chan N, Drlica-Wagner A, Wang J, Li X, Drlica K (2006) Lethal action of quinolones against a temperature-sensitive dnaB replication mutant of Escherichia coli. Antimicrob Agents Chemother 50: 362-64.

[13] Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K., Zhao, X*. (2005). Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquistion of resistance.Journal of Antimicribial Chemotherapy.56: 1172-1175.

[14] Zhao X, Drlica K (2002) Restricting the selection of antimicrobial-resistant mutant bacteria: measurement and potential use of the mutant selection window.J Infect Dis 185: 561-5.

[15] Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33: S147-56.

[16] Zhao X, Xu C, Domagala J, Drlica K (1997) DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 94: 13991-6.

[17] Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones.Microbiol Mol Biol Revs 61: 377-92.

获奖情况:

[1] InnoCentive Extraordinary & Unorthodox Philanthropy Challenge Award (2011, 美国)

[2] NIH Director’s New Innovator Award (2010, 美国)

[3] Bill & Melinda Gates Foundation Grand Challenge Exploration Award (2008、2009, 美国)

微信扫一扫
关注国重室公众号